EN | TR
E-ISSN: 2587-0262
COVİD - 19 from Rheumatology Perspective
PDF
Cite
Share
Request
Review Article
VOLUME: 8 ISSUE: 3
P: 557-563
December 2020

COVİD - 19 from Rheumatology Perspective

Namik Kemal Med J 2020;8(3):557-563
DOI: 10.37696/nkmj.747792
Mehmet Engin TEZCAN 1
Rıdvan MERCAN 2
1. Sağlık Bilimleri Üniversitesi, İstanbul Kartal Dr. Lütfi Kırdar Şehir Hastanesi, Romatoloji Kliniği, İstanbul, TÜRKİYE.
2. Tekirdağ Namık Kemal Üniversitesi, Tıp Fakültesi, İç Hastalıkları ABD, Romatoloji BD, Tekirdağ, TÜRKİYE.
No information available.
No information available
Received Date: 04.06.2020
Accepted Date: 15.10.2020
PDF
Cite
Share
Request

ABSTRACT

World Health Organization declared coronavirus disease-19 (COVID-19) as pandemic since 11 March 2020. Herein, new human coronavirus, SARS-CoV2 is the etiologic agent of the disease. Also, it has been a global health problem since it was detected in Chinese province of Wuhan at December 2019. COVID-19 has several different clinical variations from mild disease to acute respiratory distress syndrome. For the treatment of the disease, several remedies have been administered. Even though, anecdotal data showed somewhat effectiveness of those drugs for the treatment of the disease, there has been no accurate scientific knowledge proofing these. Therefore, main purpose of this review was discussing how the physicians arrange the therapies of the rheumatologic diseases during COVID-19, especially while patients are under immunosuppressive drugs. Also, we summarized the current data about the effectiveness of immunosuppressive drugs on COVID-19.